Market Research Logo

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2015

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2015’, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acute Renal Failure (ARF) (Acute Kidney Injury) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acute Renal Failure (ARF) (Acute Kidney Injury) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Acute Renal Failure (ARF) (Acute Kidney Injury) Overview
Therapeutics Development
Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview
Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Development by Companies
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Investigation by Universities/Institutes
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Development by Companies
Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Investigation by Universities/Institutes
Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development
A1M Pharma AB
Adrenomed AG
Am-Pharma B.V.
Angion Biomedica Corp.
Bolder Biotechnology, Inc.
Cellmid Limited
Complexa, Inc.
DiaMedica Inc.
Digna Biotech, S.L.
DURECT Corporation
F. Hoffmann-La Roche Ltd.
G1 Therapeutics, Inc.
Hadasit Medical Research Services & Development Ltd
Kringle Pharma, Inc.
NephroGenex, Inc.
NeuroVive Pharmaceutical AB
Noorik Biopharmaceuticals AG
Nyken BV
Opsona Therapeutics Limited
Orion Oyj
ProMetic Life Sciences Inc.
Quark Pharmaceuticals, Inc.
STATegics, Inc.
Thrasos, Inc.
Torrent Pharmaceuticals Limited
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A1M-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adrecizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BB-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BBT-030 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BBT-045 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CAB-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cardiotrophin-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Activate Wnt7b for Kidney Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CXA-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cyclosporine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DM-199 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DUR-928 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HYPER-IL-6 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KP-100IT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
levosimendan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MTP-131 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NYK-1341 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OPN-305 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PBI-4419 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pyridoxamine dihydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
QPI-1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R-190 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Alkaline Phosphatase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute Kidney Injury, Acute radiation syndrome and Ischemic organ injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RLS-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RO-6839328 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STSE-15 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THR-184 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRC-160334 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acute Renal Failure (ARF) (Acute Kidney Injury) - Recent Pipeline Updates
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products
Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones
Featured News & Press Releases
Jul 07, 2015: Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study for Acute Kidney Injury
Jun 09, 2015: Angion Biomedica To Commence Phase 2 Clinical Trial of BB3 in Acute Kidney Injury
Mar 27, 2015: NephroGenex Announces Data on Acute Kidney Injury at National Kidney Foundation 2015 Spring Clinical Meetings
Feb 23, 2015: Opsona Therapeutics Patent issued in USA covering an antibody directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof
Feb 18, 2015: Opsona Therapeutics Patent issued in US and EU covering the Opsona-developed antibody OPN-305, which is directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof
Feb 02, 2015: DiaMedica to Expand Focus of DM199 Development into Acute Vascular Diseases
Jan 20, 2015: AM-Pharma starts Adaptive Phase II trial of recAP in Acute Kidney Injury
Dec 15, 2014: Complexa Initiates Phase 1B Study of CXA-10 in Acute Kidney Injury
Nov 13, 2014: AM-Pharma Presents Preclinical Data On Mode-Of-Action For RecAP In Acute Kidney Injury
Sep 16, 2014: Thrasos Announces Successful Formal Interim Analysis and Clinical Update for Phase 2 Study of THR-184 for Acute Kidney Injury
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2015
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB, H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Adrenomed AG, H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma B.V., H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp., H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Bolder Biotechnology, Inc., H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Limited, H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Complexa, Inc., H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DiaMedica Inc., H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Digna Biotech, S.L., H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DURECT Corporation, H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by G1 Therapeutics, Inc., H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma, Inc., H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NephroGenex, Inc., H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NeuroVive Pharmaceutical AB, H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Noorik Biopharmaceuticals AG, H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Nyken BV, H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Opsona Therapeutics Limited, H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Orion Oyj, H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by ProMetic Life Sciences Inc., H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals, Inc., H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics, Inc., H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Thrasos, Inc., H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics - Recent Pipeline Updates, H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H2 2015
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2015
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report